Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05995782
Other study ID # FB418_P101
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date December 2023
Est. completion date December 2024

Study information

Verified date August 2023
Source 1ST Biotherapeutics, Inc.
Contact 1STBIO information team
Phone +82-31-895-4677
Email info@1stbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects.


Description:

Part A: Primary: To assess the safety and tolerability of single ascending oral doses of FB418 in healthy adult subjects and healthy elderly subjects. Secondary: To assess the pharmacokinetics (PK) of FB418 and metabolite after single ascending oral doses of FB418 in healthy adult subjects and healthy elderly subjects. To assess the effect of a high-fat meal on the PK of FB418 and metabolite after a single oral dose of FB418 when administered to healthy adult subjects. Part B: Primary: To assess the safety and tolerability of multiple ascending oral doses FB418 in healthy adult subjects. Secondary: To assess the PK of FB418 and metabolite after multiple ascending oral doses of FB418 in healthy adult subjects.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 64
Est. completion date December 2024
Est. primary completion date September 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years and older
Eligibility Key Inclusion Criteria: 1. Healthy, adult, male 19 55 years of age, inclusive, at the screening. 2. For elderly subjects(Part A Cohort 5 only), healthy, elderly, male or female (of non childbearing potential only) over 60 years of age, inclusive, at screening. 3. In the case of the elderly(Part A Cohort 5 only), they have a history of mild disease, but can participate if the researcher judges that they can stop taking the drug at least 2 weeks before the expected first dose or before the half-life is 5 times or more) 4. The continuous non smoker who have not used nicotine containing products for at least 3 months prior to (the first) dosing and throughout the study are based on subjective self reporting. 5. Body mass index (BMI) = 18 and = 32 kg/m2 at the screening. 6. Medically healthy with no clinically significant medical history, physical examination, simplified neurological examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee. 7. In Cohort 5, A female subject must be of non childbearing potential Key Exclusion Criteria: 1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study. 2. History or presence of a clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee. 3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study. 4. Is at suicidal risk in the opinion of the PI as per the following criteria: 1. Any suicide attempts within 12 months prior to screening or any suicidal intent, including a plan, within 3 months prior to screening. 2. C-SSRS answer of "YES" on suicidal ideation within 3 months prior to screening. 5. History or presence of alcoholism or drug abuse within the past 2 years prior to (the first) dosing. 6. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds. 7. History of seizures (childhood febrile seizures are excepted). 8. Positive urine drug or alcohol results at screening or check in. 9. Has an abnormal screening ECG indicating a second- or third- degree AV block, or one or more of the following: QRS > 120 msec, QTcF > 450 msec for males and > 460 msec for females, PR interval > 220 msec. Any rhythm other than normal sinus rhythm, which is interpreted by the PI or designee to be clinically significant at screening or check-in. 10. Has any medical or surgical condition in which lumbar puncture is contraindicated in the opinion of the PI.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FB418
Oral dose

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
1ST Biotherapeutics, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment Emergent Adverse Events (TEAE) Number of TEAEs including serious adverse events (SAEs) Up to 7 ~ 14 days after the last dose
Secondary PK parameter 1 Maximum observed concentration (Cmax) of FB418 in plasma Up to 72 hours after the last dose
Secondary PK parameter 2 Time to maximum observed concentration (Tmax) of FB418 in plasma Up to 72 hours after the last dose
Secondary PK parameter 3 The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-8) of FB418 in plasma Up to 72 hours after the last dose
Secondary PK parameter 4 Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC[0-last]) of FB418 in plasma Up to 72 hours after the last dose
Secondary PK parameter 5 Apparent terminal elimination half-life (t1/2) of FB418 in plasma Up to 72 hours after the last dose
See also
  Status Clinical Trial Phase
Completed NCT02365922 - Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Completed NCT01699451 - DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida
Completed NCT04577404 - Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) Phase 3
Terminated NCT03580616 - Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT02118805 - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Completed NCT01884571 - Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT00244244 - A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS Phase 2
Active, not recruiting NCT00420719 - Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS) N/A
Completed NCT02936635 - A Study for Patients Who Completed VITALITY-ALS (CY 4031) Phase 3
Withdrawn NCT04055532 - Biomarkers in Neurodegenerative Diseases
Completed NCT03645031 - Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease N/A
Completed NCT01786603 - Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT02559869 - Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
Completed NCT01592552 - A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
Completed NCT00403104 - Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT02424669 - Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients N/A
Completed NCT02017912 - Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS Phase 2
Completed NCT01366027 - PRISM Registry: Pseudobulbar Affect Registry Series N/A
Completed NCT00330681 - Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Phase 3
Completed NCT00876772 - Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) Phase 2/Phase 3